Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2017 August ; 26(8): 1312–1320. doi:
10.1158/1055-9965.EPI-17-0081.

Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses

Laura Sichero, PhD¹, Mariam El-Zein, PhD², Emily M. Nunes, MSc¹, Silvaneide Ferreira¹,
Eduardo L. Franco, PhD², Luisa L. Villa, PhD^{1,3}, and the Ludwig-McGill Cohort Study*

¹Center for Translational Investigation in Oncology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

²Division of Cancer Epidemiology, McGill University, Montreal, Canada

³Department of Radiology and Oncology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Abstract

Background—Alpha-human papillomavirus (α-HPV) play a causal role in cervical cancer but little is known about the epidemiology of genital Beta-HPV infection.

Methods—We used Luminex and polymerase chain reaction (PCR) hybridization to detect β- and α-HPVs prevalence at enrolment and 12-months follow-up in cervical samples from 505 women enrolled in the Ludwig-McGill cohort study. We compared epidemiological correlates of both β- and α-HPVs and compared genotypes between these genera with respect to co-occurrence and association with cervical cytological abnormalities.

Results—Infection with β-HPV types was more prevalent than that with α-HPV types at both visits (cumulative prevalences: 27.3% vs. 21.6%, respectively, $P=0.034$). β-HPVs were mostly transient, however, only 1.98% women retained their original positivity at 12 months, whereas, persistence was higher for α-HPVs (5.15%) ($P = 0.007$). Age, parity, and sexual activity variables were predictors of α-HPV but not of β-HPV. α- and β-HPV types occurred independently. Increased risk of cervical abnormalities was restricted to women infected with α-9 or α-6 HPV types. We found no epidemiological correlates for β-HPV infections.

Correspondence to: Laura Sichero, PhD, Center for Translational Investigation in Oncology, Instituto do Câncer do Estado de São Paulo., Av Dr Arnaldo, 251- Cerqueira César, São Paulo (SP) - CEP: 01246-000 - Brazil, Phone: +5511-38933010, laura.sichero@hc.fm.usp.br.

***For the Ludwig-McGill Cohort Study:** Ludwig-McGill Cohort Study Team Members: Affiliated with the Ludwig Institute for Cancer Research in Sao Paulo, Brazil: Maria Luiza Baggio, Lenice Galan, João Simão Sobrinho, José Carlos Mann Prado, Lara Termini, Maria Cecília Costa, Romulo Miyamura, Andrea Trevisan, Patricia Thomann, João Candeias, Laura Sichero, Paula Rahal, Antonio Ruiz, Jane Kaiano, Monica Santos, Patricia Savio, Paulo Maciag, Tatiana Rabachini, Luisa Villa (Co-Principal Investigator). Affiliated with McGill University in Montreal, Canada: Mariam El-Zein, Marie-Claude Rousseau, Salaheddin Mahmud, Nicolas Schlecht, Helen Trotter, Harriet Richardson, Alex Ferenczy, Thomas Rohan, Myriam Chevarie-Davis, Karolina Louvanto, Joseph Tota, Eileen Shaw, Agnihotram Ramanakumar, Eliane Duarte, Sophie Kulaga, Juliette Robitaille, Eduardo Franco (Principal Investigator).

Conflict of Interest Statement: ELF and LLV are members of the Scientific Advisory Board of Merck Co. for HPV vaccines. ELF is an occasional consultant to Roche and BD on HPV diagnostics. None of the other authors have conflicts of interest to report.

Conclusions—Detection of β -HPV types in the cervix tends to occur as random and transient episodes not explained via the sexual-transmission correlates that characterize infections by α -HPVs.

Impact—Although it is plausible that β -HPVs may play a direct or indirect carcinogenic role the lack of epidemiological correlates for detection episodes of these viruses and lack of association with cervical lesions speak against their ancillary role as sexually transmitted agents in cervical carcinogenesis.

Keywords

human papillomavirus; cutaneous HPV; β -HPV prevalence; cervical lesions; risk factors; cohort study

Introduction

Over 200 human papillomavirus (HPV) genotypes (types for short) have been characterized, of which the great majority clusters phylogenetically within three genera of the *Papillomaviridae* family: Alpha (α)-, Beta (β)-, and Gamma (γ)-HPV (1). The α genus contains HPV types that infect mostly mucosal and genital regions, including 25 oncogenic types with an established, probable, or possible role in the etiology of cervical cancer (2). β - and γ genera include HPV types that commonly infect the dry skin; they are commonly referred to as cutaneous HPVs. To date, 52 β - and 82 γ -HPVs have been identified. Thus, in combination cutaneous HPVs are a more diverse group than α -HPVs (65 types) (<http://www.hpvcenter.se/html/refclones.html>). HPV5 and HPV8 (included in the β -1 species) are recognized as possible etiological agents in cutaneous squamous cell carcinoma (SCC) in epidermodysplasia verruciformis (EV) primarily in sun-exposed areas (3). However, the role of specific β -HPV types in cutaneous SCC among immunocompromised non-EV and immunocompetent individuals has proven difficult to demonstrate because of the high viral diversity and ubiquity of multiple types in healthy skin, oral cavity, male anogenital region and condylomas (3–8).

Although most research on oncogenic potential and disease association has focused on α -HPVs, there is interest in identifying a role of non- α HPV types in the pathogenesis of benign and malignant lesions. It has been hypothesized that, instead of contributing directly to cancer development, β -HPVs may play a role solely at early stages of carcinogenesis, thus allowing the accumulation of mutations and destabilization of the host genome, ultimately driving tumorigenesis (9–13).

The objective of the current study was to describe the prevalence, distribution, and persistence of β -HPV types in DNA from cervical samples among asymptomatic women enrolled in the Ludwig-McGill Cohort Study, and compare these to cervical α -HPV types and species. We examined demographic and behavioral correlates of both β - and α -HPV types, and compared them with respect to their association with precancerous cytological abnormalities.

Materials and Methods

Study design and participants

The study sample consisted of a subset of women enrolled in the Ludwig-McGill Cohort Study, a longitudinal investigation of the natural history of HPV infection and precursor lesions of cervical cancer. A detailed description of the study design and methods can be found elsewhere (14). Briefly, 2462 women aged 18–60 years were recruited from family medicine, gynecology, and family planning clinics in Sao Paulo, Brazil from 1993 to 1997. Participants were followed up every four months in the first year following enrollment, and then twice yearly, for up to 10 years. Questionnaires were administered and biological specimens were collected. The study was approved by ethical review boards of the participating institutions in Brazil and Canada and informed consent was obtained from all participants. Supplementary Figure S1 provides an overview of the sample selection strategy. Of the 2462 women enrolled, only those with complete data (questionnaire and genotyping) at both visits, and whose samples were considered adequate (i.e., β -globin positive) were considered eligible for the current analysis. In addition, the enrollment and follow-up visits had to be within 10 days of one exact year apart (i.e., 355 days and 375 days) to permit the assessment of 12-month infection persistence. The analysis sample thus included 505 women randomly selected from 1160 women who had completed the first and fourth visit (referred to hereafter as enrollment and follow up visit, respectively) within the first year. Samples from original cohort visits two and three were not tested.

HPV genotyping

DNA was extracted from exfoliated cervical cells by spin column chromatography. Mucosal α -HPVs were tested by polymerase chain reaction (PCR) amplification with MY09/11 and PGMY09/11 primers followed by genotyping via hybridization with HPV type-specific oligonucleotide probes and restriction fragment length polymorphism analysis. In combination, these two techniques allow the identification of potentially more than 40 genital α -HPV types, which were classified as per the following species: α -1: HPVs 32, 42; α -3: HPVs 61, 62, 72, 81, 83, 84, 89; α -4: HPV57; α -5: HPVs 26, 51, 69, 82; α -6: HPVs 53, 56, 66; α -7: HPVs 18, 39, 45, 59, 68, 70; α -8: HPV40; α -9: HPVs 16, 31, 33, 35, 52, 58, 67; α -10: HPVs 6, 11, 44; α -11: HPVs 34, 73; α -13: HPV54; and α -14: HPV71 (15). The presence of cutaneous β -HPVs was determined by a type-specific, multiplex genotyping PCR assay using a mixture of specific biotinylated primers that amplify a 180 to 280 bp fragment of the *E7* gene, followed by genotyping via a bead-based Luminex technology (16). This assay distinguishes 43 β -HPV types (species β -1: HPVs 5, 8, 12, 14, 19, 20, 21, 24, 25, 36, 47, 93, 98, 99, 105, 118, 124, 143; species β -2: HPVs 9, 15, 17, 22, 23, 37, 38, 80, 100, 104, 107, 110, 111, 113, 120, 122, 145, 151; species β -3: HPVs 49, 75, 76, 115; species β -4: HPV92; and species β -5: HPVs 96, 150). We included negative and positive controls to ascertain the quality of template DNA (17).

Statistical analysis

We calculated descriptive statistics to summarize the baseline characteristics of the study sample and prevalence rates at enrollment and follow-up for all individual HPV types and by grouping them as species within each genus. We constructed scatter plots to display the

correlation between prevalence of individual HPV types between enrollment and one-year follow-up visits separately for each genus. We tested the statistical strength and significance of the correlations by calculating nonparametric Spearman's rank correlation coefficients and respective P values. We examined the tendency for infections of HPV types of each genus to persist by calculating ratios of observed to expected frequencies and respective 95% confidence intervals. Expected frequencies were based on the assumption of independence of observations between the enrolment and one-year visits. We also assessed whether infections with β -HPV and α -HPV types tended to co-occur in the same women by comparing observed and expected frequencies based on the period prevalence data for both visits. This analysis was done for individual types and for types grouped within their respective species.

We used unconditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for univariate associations between baseline characteristics, as independent variables, and the one-year period prevalence of HPV infection according to genus, as outcome. The referent category consisted of women without the respective genus-specific HPV infection. In separate logistic models we examined the association between genus-specific HPV species (as independent variables) and cervical cytological abnormalities (as outcome) using two definitions for an abnormal cytology: Atypical Cells of Undetermined Significance (ASC-US) or worse and Low grade Squamous Intraepithelial Lesion (LSIL) or worse. For each, two types of analyses were performed; unrestricted and restricted. In the former, women with infections with types belonging to a given species were compared to all others as referent, i.e., those who did not have infections with types of that species. In the restricted analysis, we used a fixed referent group of HPV negative women (n=396 for α -species, n=367 for β -species). Statistical analysis was performed using Stata version 13 (StataCorp, College Station, TX, USA).

Role of the funding source

The funders of the study had no involvement in study design; in the collection, analysis, and interpretation of data; neither in the writing of the report; and in the decision to submit the paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Table 1 presents characteristics of the study sample. The mean age of subjects was 33.5 years (range: 18–57). The majority was white and had at least elementary school education. Slightly more than half of the women reported ever smoking cigarettes. Only 15.8% of women were never or only once pregnant; 83.6% reported at least two pregnancies. Almost half of the women had none or one lifetime sexual partner and most reported no previous sexually-transmitted diseases.

Tables 2 and 3 show the prevalence of infection with β - and α -HPVs, respectively, at each visit, as well as the positivity at both enrollment and follow-up (presumed as persistent infections) and positivity at either enrollment or follow-up (used for estimating period prevalence). Among the 43 β -HPVs detectable by the assay, 14 viral types were not found.

The most prevalent types were HPV21 (β -1 species), HPV22 and HPV38 (both from β -2 species). The point prevalence of infection with any β -HPV type was just under 15% at each of the two visits, whereas the same estimates were just over 13% for any α -HPV. Overall, considering both visits as period prevalence, β -HPVs were more common than α -HPVs: 27.3% vs. 21.6%, respectively ($P=0.034$).

β -HPV infection was mostly a transient finding: 1.98% of women retained their original positivity at 12 months (Table 2). On the other hand, persistence was higher for α -HPVs (5.15%) ($P = 0.007$) (Table 3). When considering as denominators the women who had at least one of the visits positive for types of the two genera the differences became more pronounced: 7.25% and 23.85%, for β -HPV and α -HPV types, respectively ($P = 0.0005$).

By examining the strength of the correlation between prevalence estimates at enrollment and follow-up it is possible to further assess the relative transience or persistence of type-specific infection episodes by HPV genus. Figure 1 shows the between-visit scatter plots of type-specific prevalence for types that were detected in at least one of the visits (i.e., period prevalence > zero). β -HPV types (Figure 1, top) had a scattered distribution, with no statistical evidence that the between-visit prevalence estimates were correlated (Spearman's correlation coefficient = 0.344; $P=0.068$). On the other hand, the equivalent estimates for α -HPVs (Figure 1, bottom) were significantly correlated (Spearman's correlation coefficient = 0.533; $P=0.0035$).

Based on the assumption that detection of a given HPV type is independent between visits, we compared the observed and expected positivity for the most common HPV types, i.e., those that were detected in at least 10 women in either the enrollment or follow-up visits (Supplementary Table S1). For none of the 7 β -HPV types included in the analysis was there evidence against the assumption of independence. On the other hand, among the 3 most common α -HPV types there was strong evidence for HPV16 that visit-specific prevalence estimates were not independent. Positivity for HPV16 in both visits was 13.3 times (95%CI: 4.87–29.02) more frequent than expected by chance. The ratio for HPV51 was 16.84 but largely imprecise (95%CI: 0.42–93.80).

We also tested whether positivity for β -HPV and α -HPV types were associated as coinfections both as individual types (Supplementary Table S2) and as grouped genus-specific species (Supplementary Table S3). None of the pairwise combinations of the most common β -HPV and α -HPV types seemed to be more common than expected (Supplementary table 2). There was also no evidence that by grouping all type-specific episodes into species between-genus coinfections became observable because of the larger sample sizes (Supplementary table 3).

Table 4 displays associations between candidate risk factors and the one-year combined positivity for α - and for β -HPVs, separately. Age and number of pregnancies were inversely associated with risk of α -HPVs. As expected, lifetime and recent (last one or five years) number of sex partners were strong predictors of an increased risk of detecting α -HPVs. Women who reported 2 sex partners in the last year were 5.03 times (95% CI=1.94–13.11) more likely to be infected with any α -HPV type compared to women with at most one

partner during the same period. In contrast, there were no clear correlates of β -HPV infection among the same women, except for an implausible reduced risk among women reporting 4 or more lifetime sexual partners.

Table 5 presents the association between HPV infection status and lesion outcome based on the worst lesion grade observed by cervical cytology during the first year of follow up. Not surprisingly, women with HPV types of the α -9 species (includes HPVs 16 and 31) were at a higher risk of developing LSIL or worse compared with HPV negative women (restricted analysis, OR=25.72, 95%CI: 7.70–85.95) or with those not harboring a viral type of α -9 species (unrestricted analysis, OR=19.69, 95%CI: 6.79–57.12). Strong associations were also observed for women infected with HPV types of α -6 species (includes HPVs 53, 56, and 66). In contrast, no significant association was found between women infected with any β -HPV species and cervical lesion risk, regardless of grade and analysis type.

Discussion

We found that cervical infection with mostly cutaneous HPV types of the β -HPV genus were relatively common among low-income Brazilian women attending an opportunistic screening program and enrolled in our cohort study. In fact, β -HPV infections were more common than those by mucosotropic α -HPV types but appear to be mostly transient episodes. Interestingly, we found no epidemiological correlates of cervical infections with β -HPV types. For construct validity, we conducted the same analyses with α -HPV types, which also served the purpose of assessing whether infection with the latter types - individually and grouped as species - was predictive of β -HPV detection. Although we observed the expected reproductive health and sexual activity correlates for α -HPV infections, none of the sociodemographic, lifestyle, behavioral, and reproductive health variables that we collected via questionnaire was predictive of β -HPV infections. Likewise, infections with α -HPV species that include carcinogenic types were associated with cervical precancerous abnormalities, whereas none of the β -HPV species was statistically associated with such findings. We also did not find any evidence that α -HPV and β -HPV types occur preferentially as coinfections. The overall point prevalence of β -HPV infections in the cervix in the present investigation (15%) was considerably lower than those we observed using the same assay methodology in a study of healthy men for the anal canal (54.3%), genitals (77.7%), external genital lesions (61.1%), as well as the oral cavity (29.3%) (5,18,19). Moreover, infection by two or more β -HPVs was not detected in the same cervical specimen despite the fact that multiple β -HPVs are commonly observed in the skin of healthy individuals and organ transplant recipients (20,21), as well as in male genitals where we detected up to 19 viral types simultaneously (3,19,22).

A limitation of the current study is that we examined 43 out of the 52 β -HPV types described up until now and did not access γ -HPV genomes. Because new HPV cutaneous types are continually characterized, this analysis possibly underestimated the frequency of untested and unknown HPVs. Additionally; short-term persistence of β -HPVs could not be evaluated as samples tested were collected 12 months apart.

Some studies have reported co-detection of α - and β -HPVs in the oral cavity and in penile cancer specimens (5,23). However, a possible role of β -HPVs as carcinogenetic co-factors augmenting that of α -HPVs at these anatomical sites remains unclear. It is conceivable that cutaneous HPV infections could affect the acquisition and/or clearance of mucosal HPVs. With this hypothesis in mind we examined the co-occurrence of α - and β -HPVs in our cohort in an attempt to identify a propensity for some types to occur more frequently as joint infections. Our findings do not support this hypothesis, as we observed that α - and β -HPV types and species occurred mostly independently of each other. This is in contrast with the recent report of a significant association between β -HPV detection and HPVs 16/18 infections at the anal canal among HIV-negative men who have sex with men (24). Similarly, in one study, detection of α -HPVs in the oral cavity significantly increased the odds of β -HPV detection (25).

Clinical manifestations of infections with certain β -HPV types include common, plantar, planar, and genital warts (26). Although recent functional in vitro studies reveal that some β -HPV types have intrinsic oncogenic potential (27,28), they tend to cause neoplastic disease at anatomic sites typically exposed to ultraviolet radiation. However, β - and γ -HPV DNA have also been detected in condylomas and other genital lesions, and seem to play a carcinogenic role in head and neck cancers (23,29,30).

Although β -HPVs were more common than α -HPVs, the latter were more likely to persist and be associated with markers of sexual activity and with cervical lesions in the current study. In contrast, β -HPVs infections were not associated with cervical abnormalities or any of a long list of putative predictors. We had observed the same lack of epidemiological or lesion correlates in a study of anogenital specimens of men (6,7). It is reasonable to suppose that β -HPVs detection in mucosal surfaces, including cervicovaginal, may reflect deposition of virions shed from cutaneous body sites and introduced by hand as part of genital hygiene. Because hair follicles are potential reservoirs of persistent HPV infection, it cannot be ruled out that some instances of β -HPV detection in our subjects may have resulted from skin/anogenital hair contamination during specimen sampling or from recent sexual activity.

In summary, detection of cervical β -HPVs was more common than α -HPVs, but detection episodes were transient, seemed to occur at random, and were not associated with risk for cervical lesions. There was no correlation between β -HPV and α -HPV detection, either at the individual type level or as grouped species. In contrast with α -HPV, which were correlated with known sexual activity markers, we found no predictors of cervical β -HPV detection. Detection of cutaneous HPVs in the cervix may be unrelated to an active infectious process and may merely represent deposition of virions or contamination during cervical sampling.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Statment: This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [Grants numbers 13/01440-4 to LS; 13/20470-1 to EMN; 08/57889-1 to LLV]; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [Grant number 573799/2008-3 to LLV]. The Ludwig-McGill Cohort Study was funded by the Ludwig Institute for Cancer Research (intramural grant to LLV and ELF), the US National Cancer Institute (grant CA70269 to ELF), and the Canadian Institutes of Health Research (grants MA-13647, MOP-49396, CRN-83320 to ELF).

References

1. Chouhy D, Bolatti EM, Pérez GR, Giri AA. Analysis of the genetic diversity and phylogenetic relationships of putative human papillomavirus types. *J Gen Virol.* 2013; 94:2480–8. [PubMed: 23997181]
2. IARC Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: International Agency for Research on Cancer; 2012.
3. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O. Cutaneous human papillomaviruses persist on healthy skin. *J Invest Dermatol.* 2007; 127:116–9. [PubMed: 17024097]
4. Antonsson A, Karanfilovska S, Lindqvist PG, Hansson B. General Acquisition of Human Papillomavirus Infections of Skin Occurs in Early Infancy. *J Clin Microbiol.* 2003; 41:2509–14. [PubMed: 12791874]
5. Bottalico D, Chen Z, Dunne A, Ostolozza J, McKinney S, Sun C, et al. The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. *J Infect Dis.* 2011; 204:787–92. [PubMed: 21844305]
6. Sichero L, Pierce Campbell CM, Fulp W, Ferreira S, Sobrinho JS, Baggio M, et al. High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study. *BMC Infect Dis.* 2014; 14:677. [PubMed: 25857319]
7. Sichero L, Nyitray AG, Nunes EM, Nepal B, Ferreira S, Sobrinho JS, et al. Diversity of human papillomavirus in the anal canal of men: the HIM Study. *Clin Microbiol Infect.* 2015; 21:502–9. [PubMed: 25698660]
8. Arroyo Mühr LS, Bzhalava D, Lagheden C, Eklund C, Johansson H, Forslund O, et al. Does human papillomavirus-negative condylomata exist? *Virology.* 2015; 485:283–8. [PubMed: 26318260]
9. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. *J Invest Dermatol.* 2011; 131:1745–53. [PubMed: 21490616]
10. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. *J Invest Dermatol.* 2005; 125:93–7. [PubMed: 15982308]
11. Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, et al. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. *J Virol.* 2012; 86:2366–70. [PubMed: 22171257]
12. Viariso D, Decker KM, Aengeneyndt B, Flechtenmacher C, Gissmann L, Tommasino M. Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. *J Gen Virol.* 2013; 94:749–52. [PubMed: 23223623]
13. Wallace NA, Robinson K, Galloway DA. Beta Human Papillomavirus E6 Expression Inhibits Stabilization of p53 and Increases Tolerance of Genomic Instability. *J Virol.* 2014; 88:6112–27. [PubMed: 24648447]
14. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. *Rev Panam Salud Publica.* 1999; 6:223–33. [PubMed: 10572472]
15. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. *J Clin Microbiol.* 2000; 38:357–61. [PubMed: 10618116]

16. Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, et al. Development of a Sensitive and Specific Multiplex PCR Method Combined with DNA Microarray Primer Extension To Detect Betapapillomavirus Types. *J Clin Microbiol.* 2007; 45:2537–44. [PubMed: 17581938]
17. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. *J Clin Microbiol.* 2010; 48:143–9. [PubMed: 19864475]
18. Pierce Campbell CM, Messina JL, Stoler MH, Jukic DM, Tommasino M, Gheit T, et al. Cutaneous human papillomavirus types detected on the surface of male external genital lesions: A case series within the HPV Infection in Men Study. *J Clin Virol.* 2013; 58:652–9. [PubMed: 24210970]
19. Nunes EM, Sudenga SL, Gheit T, Tommasino M, Baggio ML, Ferreira S, et al. Diversity of Beta-papillomavirus at anogenital and oral anatomic sites of men: The HIM Study. *Virology.* 2016; 495:33–41. [PubMed: 27161202]
20. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. *J Med Virol.* 2000; 61:289–97. [PubMed: 10861635]
21. Weissenborn S, Neale RE, Waterboer T, Abeni D, Bavinck JN, Green AC, et al. Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. *Med Microbiol Immunol.* 2012; 201:117–25. [PubMed: 21792749]
22. Hampras SS, Giuliano AR, Lin HY, Fisher KJ, Abrahamsen ME, Sirak BA, et al. Natural History of Cutaneous Human Papillomavirus (HPV) Infection in Men: The HIM Study. *PLoS One.* 2014; 9:e104843. [PubMed: 25198694]
23. Heideman DA, Waterboer T, Pawlita M, Delis-van Diemen P, Nindl I, Leijte JA, et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. *J Clin Oncol.* 2007; 25:4550–6. [PubMed: 17925550]
24. Donà MG, Gheit T, Latini A, Benevolo M, Torres M, Smelov V, et al. Alpha, beta and gamma Human Papillomaviruses in the anal canal of HIV-infected and uninfected men who have sex with men. *J Infect.* 2015; 71:74–84. [PubMed: 25698067]
25. Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, et al. Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. *J Infect Dis.* 2013; 208:1643–52. [PubMed: 24014882]
26. Cardoso JC, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. *Acta Dermatovenerol Alp Pannonica Adriat.* 2011; 20:145–54. [PubMed: 22131115]
27. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, et al. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. *EMBO Rep.* 2006; 7:334–40. [PubMed: 16397624]
28. Viarisis D, Decker KM, Aengeneyndt B, Flechtenmacher C, Gissmann L, Tommasino M. Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. *J Gen Virol.* 2013; 94:749–52. [PubMed: 23223623]
29. Sturegård E, Johansson H, Ekström J, Hansson BG, Johnsson A, Gustafsson E, et al. Human papillomavirus typing in reporting of condyloma. *Sex Transm Dis.* 2013; 40:123–9. [PubMed: 23324975]
30. Agalliu I, Gapstur S, Chen Z, Wang T, Anderson RL, Teras L, et al. Associations of Oral α -, β -, and γ -Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. *JAMA Oncol.* 2016; 2:599–606.

Figure 1.

Correlation between enrollment and one-year follow-up prevalence of type-specific HPV infections in the Ludwig-McGill Cohort Study (n=505). Top: β -HPV types, Bottom: α -HPV types (only types detected in either of the two visits were included).

Table 1

Characteristics of the study sample at baseline in the Ludwig-McGill Cohort Study (n = 505)

Variables	Categories	n (%) ^a
Age (years)	18–22	62 (12.3)
	22–29	121 (24.0)
	30–39	186 (36.8)
	40	136 (26.9)
Ethnicity	White	318 (63.0)
	Non-white	187 (37.0)
Education	< Elementary	125 (24.8)
	Elementary	301 (59.6)
	High school	68 (13.5)
	College/University	9 (1.8)
Smoking	Never	245 (48.5)
	Current	172 (34.1)
	Former	88 (17.4)
Number of pregnancies	0–1	80 (15.8)
	2–3	225 (44.6)
	4–6	147 (29.1)
	7	50 (9.9)
Oral contraceptive use	Never	85 (16.8)
	< 6 years	261 (51.7)
	6 years	159 (31.5)
Condom use	No	185 (36.6)
	Yes	320 (63.4)
Hygienic tampon use	No	454 (89.9)
	Yes	50 (9.9)
Menstrual cloth use	No	313 (62.0)
	Yes	191 (37.8)
Vaginal douching	Never/occasional	475 (94.1)
	Frequent	30 (5.9)
Age at first intercourse	20–50	142 (28.1)
	18–19	113 (22.4)
	16–17	113 (22.4)
	15	137 (27.1)
Lifetime number of sex partners	0–1	238 (47.1)
	2–3	176 (34.9)
	4+	91 (18.0)
Number of sex partners in the last 5 years	0–1	410 (81.2)
	2	95 (18.8)
Number of sex partners in the last year	0–1	483 (95.6)
	2	18 (3.6)

Variables	Categories	n (%) ^a
Anal sex practiced between visits	No	301 (59.6)
	Yes	204 (40.4)
Lifetime number of anal sex partners	0	319 (63.2)
	1	172 (34.1)
	2–3	14 (2.8)
Received oral sex	Never	239 (47.3)
	Ever	266 (52.7)
Annual frequency of masturbation acts in the last 5 years ^b	0	351 (69.5)
	< 1	92 (18.2)
	1–9	27 (5.3)
	10–35	19 (3.8)
	36	16 (3.2)
History of sexually transmitted diseases	No	384 (76.0)
	HPV-related	20 (4.0)
	Other	100 (19.8)
Cytology grade ^c	NILM	471 (93.3)
	ASC-US	16 (3.2)
	LSIL	13 (2.6)
	HSIL	3 (0.6)

Abbreviations: ASC-US: Atypical Cells of Undetermined Significance; HSIL: High Squamous Intraepithelial Lesion; LSIL: Low Squamous Intraepithelial Lesion; NILM: Negative for Intraepithelial Lesion or Malignancy

^aFrequencies may not add up to 505 women because of missing values for some variables.

^bQuestion asked at the follow-up visit. Of those practicing masturbation, 147 reported using hands and 6 using objects (1 missing).

^cRefers to the highest cytological grade attained during the first year.

Table 2Prevalence of infection [n (%)] with β -HPV types and species in the Ludwig-McGill Cohort Study (n=505)

Type-specific β -HPV	Positivity at enrollment	Positivity at 1-year follow-up	Positivity at enrollment AND follow-up	Positivity at enrollment OR follow-up
HPV5	5 (0.99)	4 (0.79)	0	9 (1.78)
HPV8	3 (0.59)	8 (1.58)	0	11 (2.18)
HPV9	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV12	2 (0.40)	4 (0.79)	0	6 (1.19)
HPV14	0	1 (0.20)	0	1 (0.20)
HPV15	3 (0.59)	0	0	3 (0.59)
HPV17	1 (0.20)	1 (0.20)	1 (0.20)	1 (0.20)
HPV19	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV20	0	0	0	0
HPV21	21 (4.16)	7 (1.39)	0	28 (5.54)
HPV22	8 (1.58)	13 (2.57)	1 (0.20)	20 (3.96)
HPV23	0	2 (0.40)	0	2 (0.40)
HPV24	3 (0.59)	7 (1.39)	0	10 (1.98)
HPV25	0	0	0	0
HPV36	0	10 (1.98)	0	10 (1.98)
HPV37	0	0	0	0
HPV38	14 (2.77)	8 (1.58)	0	22 (4.36)
HPV47	0	2 (0.40)	0	2 (0.40)
HPV49	1 (0.20)	0	0	1 (0.20)
HPV75	0	0	0	0
HPV76	3 (0.59)	6 (1.19)	0	9 (1.78)
HPV80	0	0	0	0
HPV92	0	1 (0.20)	0	1 (0.20)
HPV93	0	0	0	0
HPV96	1 (0.20)	2 (0.40)	0	3 (0.59)
HPV98	0	0	0	0
HPV99	0	0	0	0
HPV100	2 (0.40)	1 (0.20)	0	3 (0.59)
HPV104	0	0	0	0
HPV105	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV107	0	2 (0.40)	0	2 (0.40)
HPV110	3 (0.59)	3 (0.59)	0	6 (1.19)
HPV111	10 (1.98)	2 (0.40)	0	12 (2.38)
HPV113	1 (0.20)	0	0	1 (0.20)
HPV115	0	0	0	0
HPV118	0	0	0	0
HPV120	2 (0.40)	1 (0.20)	0	3 (0.59)
HPV122	0	7 (1.39)	0	7 (1.39)
HPV124	1 (0.20)	0	0	1 (0.20)

Type-specific β -HPV	Positivity at enrollment	Positivity at 1-year follow-up	Positivity at enrollment AND follow-up	Positivity at enrollment OR follow-up
HPV143	0	0	0	0
HPV145	0	0	0	0
HPV150	0	0	0	0
HPV151	1 (0.20)	0	0	1 (0.20)
β -HPV species ^a				
β -1	33 (6.53)	39 (7.72)	3 (0.59)	69 (13.66)
β -2	44 (8.71)	37 (7.33)	5 (0.99)	76 (15.05)
β -3	4 (0.79)	6 (1.19)	0	10 (1.98)
β -4	0	1 (0.20)	0	1 (0.20)
β -5	1 (0.20)	2 (0.40)	0	3 (0.59)
Any β -HPV	75 (14.85)	73 (14.46)	10 (1.98)	138 (27.33)

^a β -HPV species: β -1 (HPVs 5, 8, 12, 14, 19, 21, 24, 36, 47, 105, 124); β -2 (HPVs 9, 15, 17, 22, 23, 38, 100, 107, 110, 111, 113, 120, 122, 151); β -3 (HPVs 49, 76); β -4 (HPV92); β -5 (HPV96).

Table 3Prevalence of infection [n (%)] with α -HPV types and species in the Ludwig-McGill Cohort Study (n=505)

Type-specific α -HPV	Positivity at enrollment	Positivity at 1-year follow-up	Positivity at enrollment AND follow-up	Positivity at enrollment OR follow-up
HPV6/11	5 (0.99)	0	0	5 (0.99)
HPV16	19 (3.76)	12 (2.38)	6 (1.19)	25 (4.95)
HPV18	3 (0.59)	2 (0.40)	0	5 (0.99)
HPV26	0	0	0	0
HPV31	3 (0.59)	5 (0.99)	1 (0.20)	7 (1.39)
HPV32	0	1 (0.20)	0	1 (0.20)
HPV33	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV34	0	0	0	0
HPV35	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV39	0	2 (0.40)	0	2 (0.40)
HPV40	2 (0.40)	2 (0.40)	1 (0.20)	3 (0.59)
HPV42	0	0	0	0
HPV44	3 (0.59)	2 (0.40)	0	5 (0.99)
HPV45	0	1 (0.20)	0	1 (0.20)
HPV51	6 (1.19)	5 (0.99)	1 (0.20)	10 (1.98)
HPV52	5 (0.99)	4 (0.79)	1 (0.20)	8 (1.58)
HPV53	8 (1.58)	7 (1.39)	0	15 (2.97)
HPV54	2 (0.40)	4 (0.79)	1 (0.20)	5 (0.99)
HPV56	1 (0.20)	4 (0.79)	1 (0.20)	4 (0.79)
HPV57	0	0	0	0
HPV58	4 (0.79)	5 (0.99)	1 (0.20)	8 (1.58)
HPV59	2 (0.40)	1 (0.20)	0	3 (0.59)
HPV61	4 (0.79)	4 (0.79)	1 (0.20)	7 (1.39)
HPV62	0	0	0	0
HPV66	4 (0.79)	1 (0.20)	0	5 (0.99)
HPV67	0	0	0	0
HPV68	0	2 (0.40)	0	2 (0.40)
HPV69	0	0	0	0
HPV70	6 (1.19)	2 (0.40)	2 (0.40)	6 (1.19)
HPV71	1 (0.20)	4 (0.79)	0	5 (0.99)
HPV72	0	1 (0.20)	0	1 (0.20)
HPV73	0	0	0	0
HPV81	1 (0.20)	1 (0.20)	0	2 (0.40)
HPV82	1 (0.20)	0	0	1 (0.20)
HPV83	0	1 (0.20)	0	1 (0.20)
HPV84	2 (0.40)	2 (0.40)	0	4 (0.79)
HPV89	0	0	0	0

 α -HPV species^a

Type-specific α -HPV	Positivity at enrollment	Positivity at 1-year follow-up	Positivity at enrollment AND follow-up	Positivity at enrollment OR follow-up
α -1	0	1 (0.20)	0	1 (0.20)
α -3	7 (1.39)	9 (1.78)	1 (0.20)	15 (2.97)
α -4	0	0	0	0
α -5	7 (1.39)	5 (0.99)	1 (0.20)	11 (2.18)
α -6	13 (2.57)	12 (2.38)	1 (0.20)	24 (4.75)
α -7	11 (2.18)	9 (1.78)	2 (0.40)	18 (3.56)
α -8	2 (0.40)	2 (0.40)	1 (0.20)	3 (0.59)
α -9	32 (6.34)	26 (5.15)	9 (1.78)	49 (9.70)
α -10	8 (1.58)	2 (0.40)	0	10 (1.98)
α -11	0	0	0	0
α -13	2 (0.40)	4 (0.79)	1 (0.20)	5 (0.99)
α -14	1 (0.20)	4 (0.79)	0	5 (0.99)
Any α -HPV	69 (13.66)	66 (13.07)	26 (5.15)	109 (21.58)

^a α -HPV species: α -1 (HPVs 32, 42); α -3 (HPVs 61, 62, 72, 81, 83, 84, 89); α -4 (HPV57); α -5 (HPVs 26, 51, 69, 82); α -6 (HPVs 53, 56, 66); α -7 (HPVs 18, 39, 45, 59, 68, 70); α -8 (HPV40); α -9 (HPVs 16, 31, 33, 35, 52, 58, 67); α -10 (HPVs 6, 11, 44); α -11 (HPVs 34, 73); α -13 (HPV54); α -14 (HPV71).

Univariate associations between subject characteristics and one-year period prevalence of HPV infection by genus in the Ludwig-McGill Cohort Study (n=505)

Table 4

Variable	Categories	α -HPV positivity (n=109)		β -HPV positivity (n=138)	
		n (%)	OR (95% CI)	n (%)	OR (95% CI)
Age (years)	18–22	24 (22.02)	1	17 (12.32)	1
	22–29	24 (22.02)	0.39 (0.20–0.77)	37 (26.81)	1.17 (0.59–2.30)
	30–39	43 (39.45)	0.48 (0.26–0.88)	45 (32.61)	0.84 (0.44–1.62)
	40	18 (16.51)	0.24 (0.12–0.49)	39 (28.26)	1.06 (0.54–2.08)
Ethnicity	White	67 (61.47)	1	90 (65.22)	1
	Non-white	42 (38.53)	1.09 (0.70–1.68)	48 (34.78)	0.87 (0.58–1.32)
Education	<elementary	21 (19.27)	1	32 (23.19)	1
	elementary	65 (59.63)	1.36 (0.79–2.35)	81 (58.70)	1.07 (0.67–1.72)
	High School	21 (19.27)	2.21 (1.10–4.44)	23 (16.67)	1.49 (0.78–2.83)
Smoking	College/University	2 (1.83)	1.41 (0.27–7.29)	2 (1.45)	0.83 (0.16–4.20)
	Never	48 (44.04)	1	67 (48.55)	1
	Current	39 (35.78)	1.20 (0.75–1.94)	41 (29.71)	0.83 (0.53–1.30)
No. pregnancies	Former	22 (20.18)	1.37 (0.77–2.43)	30 (21.74)	1.37 (0.81–2.32)
	0–1	27 (24.77)	1	21 (15.22)	1
	2–3	49 (44.95)	0.55 (0.31–0.96)	65 (47.10)	1.14 (0.64–2.03)
	4–6	19 (17.43)	0.29 (0.15–0.57)	44 (31.88)	1.20 (0.65–2.21)
	7	13 (11.93)	0.69 (0.31–1.51)	7 (5.07)	0.46 (0.18–1.17)
Oral contraceptive use	Never	20 (18.35)	1	26 (18.84)	1
	<6 years	60 (55.05)	0.97 (0.54–1.73)	74 (53.62)	0.90 (0.53–1.53)
	6 years	29 (26.61)	0.73 (0.38–1.38)	38 (27.54)	0.71 (0.40–1.28)
Condom use	No	30 (27.52)	1	54 (39.13)	1
	Yes	79 (72.48)	1.69 (1.06–2.70)	84 (60.87)	0.86 (0.58–1.29)
Hygienic tampon use	No	89 (81.7)	1	128 (92.8)	1
	Yes	20 (18.3)	2.73 (1.48–5.04)	10 (7.2)	0.64 (0.31–1.31)
Menstrual cloth use	No	74 (67.9)	1	89 (64.5)	1
	Yes	35 (32.1)	0.72 (0.46–1.14)	49 (35.5)	0.87 (0.58–1.30)

Variable	Categories	α -HPV positivity (n=109)		β -HPV positivity (n=138)	
		n (%)	OR (95% CI)	n (%)	OR (95% CI)
Vaginal douching	Never/occasional	98 (89.9)	1	132 (95.7)	1
	Frequent	11 (10.1)	2.23 (1.03–4.83)	6 (4.3)	0.65 (0.26–1.62)
Age at first intercourse	20–50	27 (24.77)	1	38 (27.54)	1
	18–19	22 (20.18)	1.03 (0.55–1.93)	31 (22.46)	1.03 (0.59–1.80)
	16–17	27 (24.77)	1.34 (0.73–2.44)	39 (28.26)	1.44 (0.84–2.47)
	15	33 (30.28)	1.35 (0.76–2.40)	30 (21.74)	0.77 (0.44–1.33)
Lifetime number of sex partners	0–1	41 (37.61)	1	73 (52.90)	1
	2–3	39 (35.78)	1.37 (0.84–2.23)	53 (38.41)	0.97 (0.64–1.49)
	4+	29 (26.61)	2.25 (1.29–3.91)	12 (8.70)	0.34 (0.18–0.67)
Sex partners in the last 5 years	0–1	71 (65.14)	1	115 (83.33)	1
	2	38 (34.86)	3.18 (1.96–5.16)	23 (16.67)	0.82 (0.49–1.37)
Sex partners in the last year	0–1	96 (88.07)	1	134 (97.10)	1
	2	10 (9.17)	5.03 (1.94–13.11)	3 (2.17)	0.52 (0.15–1.83)
Anal sex practiced between visits	No	61 (56.0)	1	81 (58.7)	1
	Yes	48 (44.0)	1.21 (0.79–1.86)	57 (41.3)	1.05 (0.70–1.58)
Lifetime number of anal sex partners	Never	67 (61.5)	1	86 (62.3)	1
	1	37 (33.9)	1.03 (0.65–1.62)	48 (34.8)	1.05 (0.69–1.59)
	2–3	5 (4.6)	2.09 (0.68–6.44)	4 (2.9)	1.08 (0.33–3.55)
	Never	47 (43.1)	1	64 (46.4)	1
Received oral sex	Ever	62 (56.9)	1.24 (0.81–1.90)	74 (53.6)	1.05 (0.72–1.56)
	0	80 (73.4)	1	97 (70.3)	1
Annual frequency of masturbation acts in the last 5 years	< 1	13 (11.9)	0.56 (0.29–1.05)	25 (18.1)	0.98 (0.58–1.64)
	1–9	6 (5.5)	0.97 (0.38–2.48)	8 (5.8)	1.10 (0.47–2.60)
	10–35	5 (4.6)	1.21 (0.42–3.46)	6 (4.3)	1.21 (0.45–3.27)
	36	5 (4.6)	1.54 (0.52–4.56)	2 (1.4)	0.37 (0.08–1.68)
History of sexually transmitted diseases	No	81 (74.31)	1	105 (76.09)	1
	HPV-STD	8 (7.34)	2.49 (0.99–6.31)	4 (2.90)	0.66 (0.22–2.03)
	Other STD	20 (18.35)	0.94 (0.54–1.62)	28 (20.29)	1.03 (0.63–1.69)

Table 5

Associations between positivity for HPV species by genus and cytological abnormalities^a in the Ludwig-McGill Cohort Study (n=503)

Genus	Species	ASC-US (n=32)			LSIL (n=16)		
		n	OR (95% CI)	Restricted analysis ^b OR (95% CI)	n	OR (95% CI)	Restricted analysis ^c OR (95% CI)
Alpha ^d	α-3	0	0.00 (0.00–4.19)	0.00 (0.00–7.90)	0	0.00 (0.00–9.12)	0.00 (0.00–42.26)
	α-5	2	3.42 (0.71–16.55)	5.63 (1.12–28.35)	1	3.18 (0.38–26.46)	9.78 (1.00–95.51)
	α-6	5	4.66 (1.61–13.51)	7.04 (2.30–21.51)	5	11.84 (3.72–37.67)	27.15 (6.72–109.79)
	α-7	1	0.86 (0.11–6.69)	1.49 (0.19–11.95)	0	0.00 (0.00–7.42)	0.00 (0.00–34.83)
	α-9	13	8.52 (3.89–18.69)	9.41 (4.15–21.35)	10	19.69 (6.79–57.12)	25.72 (7.70–85.95)
Beta ^e	β-1	4	0.91 (0.31–2.68)	0.93 (0.31–2.79)	0	0.00 (0.00–1.64)	0.00 (0.00–1.61)
	β-2	6	1.34 (0.53–3.39)	1.30 (0.51–3.30)	2	0.81 (0.18–3.64)	0.69 (0.15–3.10)
	β-3	1	1.66 (0.20–13.49)	1.66 (0.20–13.65)	0	0.00 (0.00–14.62)	0.00 (0.00–12.52)

^aCytological outcome defined at two cut-off-points (ASC-US: Atypical Cells of Undetermined Significance, LSIL: Low Squamous Intraepithelial Lesion). Two women had missing data on cytology.

^bUnrestricted analysis compared women with a genus-specific species infection against a floating referent group of all women who did not have that particular species infection.

^cRestricted analysis compared women with a genus-specific species infection against a fixed referent group of HPV negative women (α referent group n=396, β negative group n=367).

^dβ-HPV species: β-1 (HPVs 5, 8, 12, 14, 19, 21, 24, 36, 47, 105, 124); β-2 (HPVs 9, 15, 17, 22, 23, 38, 100, 107, 110, 111, 113, 120, 122, 151); β-3 (HPVs 49, 76).

^eα-HPV species: α-3 (HPVs 61, 62, 72, 81, 83, 84, 89); α-5 (HPVs 26, 51, 69, 82); α-6 (HPVs 53, 56, 66); α-7 (HPVs 18, 39, 45, 59, 68, 70); α-9 (HPVs 16, 31, 33, 35, 52, 58, 67); α-10 (HPVs 6, 11, 44).